Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema
Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Up to now alpha 1-antitrypsin (AAT) augmentation therapy has been approved only for commercial use in selected adults with severe AAT deficiency-related pulmonary emphysema (i.e. PI*ZZ genotypes as well as combinations of Z, rare and null alleles expressing AAT serum concentrations <11 μmol/L). However, the compassionate use of augmentation therapy...
Alternative Titles
Full title
Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_673ba3605d904eabace8df8897f5d877
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_673ba3605d904eabace8df8897f5d877
Other Identifiers
ISSN
1750-1172
E-ISSN
1750-1172
DOI
10.1186/1750-1172-6-14
